A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Encenicline (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 25 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Planned primary completion date changed from 1 May 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.